NCT04981509 2026-03-18
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
18 trialsNCT01130519 2025-02-21
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT00749892 2020-09-10
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00087035 2020-08-03
Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00088946 2020-07-31
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02169284 2020-07-07
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02689336 2019-09-09
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Washington University School of Medicine
Phase 2 Withdrawn
NCT01688973 2019-01-03
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00272038 2018-06-27
Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
Oncology Specialists, S.C.
Phase 2 Completed
NCT00380029 2017-07-19
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00425386 2017-05-03
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00081614 2014-05-16
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00353301 2014-04-14
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Phase 2 Completed
NCT00193154 2014-04-01
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00045487 2014-01-27
OSI-774
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT00060307 2013-02-28
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00148772 2011-06-28
Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy
Endeavor Health
Phase 2 Completed